Health Canada approved epcoritamab plus lenalidomide and rituximab for relapsed/refractory grade 1 to 3a follicular lymphoma, backed by the EPCORE FL-1 trial.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
Follicular lymphoma is second among the most common subtypes of non-Hodgkin's lymphoma (NHL), accounting for about 20 to 25% of non-Hodgkin's lymphoma.